LONDON – Convergence Pharmaceuticals Ltd. is laying plans to raise £40 million to £50 million (US$68 million to $84 million) for a phase IIb/III trial of its sodium channel blocker CNV1014802, after reporting positive results in a phase II study of patients suffering severe facial pain trigeminal neuralgia (TGN).